11,682 trials (keyword fallback)
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Acute Respiratory Distress Syndrome · Acute Lung Injury
Primary: Oxygenation — 10 Participants
NSCLC · Solid Tumors
Primary: Phase 1 Safe and Tolerable Phase 2 Dose. — 10 mg/m^2
Cystic Fibrosis
Primary: Feasibility of Participants Completing 2-week Study Visit — 25; 25; 0 Participants
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Non-Small Cell Lung Cancer · Malignant Melanoma · Head and Neck Squamous Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg
COPD · Chronic Bronchitis · Emphysema
Primary: Macrophage Activation, TNF-a — 6.1; 3.8; 2.6 ng/ml — p=0.05
Non-small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.3; 14 Weeks
Extensive Stage Small Cell Lung Carcinoma · Large Cell Lung Carcinoma · Neuroendocrine Carcinoma
Primary: Recommended Phase II Dose (Phase I) — 100 mg
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Video-assisted Thoracoscopic Surgery · Lung Isolation Device · One-lung Ventilation
Primary: Time to Obtain Complete Lung Collapse — 47.8; 32.5 minutes
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8
Primary: Overall Survival (OS) — 11.6; 14.5 months — p=0.05
Non-Small Cell Lung Cancer
Primary: Duration of Treatment of Anti-cancer Drugs — 11; 14; 9.4; 15.8 Months
Ewing Sarcoma · PEComa · Epithelioid Sarcoma
Primary: Maximum Tolerated Dose of ABI-009 — 100 mg/m^2